Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes.

Next Previous
Trial Profile

DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Otelixizumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms DEFEND 2A; DEFEND-2
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 06 Apr 2022 This trial has been completed in Netherland (Global end date: 09/03/2012), according to European Clinical Trials Database record.
  • 06 Apr 2022 This trial has been completed in Netherland (Global end date: 09/03/2012), according to European Clinical Trials Database record.
  • 01 Nov 2016 Results of urinary C-peptide analysis published in the Diabetic Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top